p.78 抽出テキスト
281. Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023;389:1167–79. https://doi.org/10.1056/NEJMoa2303062 282. Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024;390:107–17. https://doi.org/10.1056/NEJMoa2310234 283. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441–8. https://doi.org/10.1001/jama.288.19.2441 284. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke prevention in atrial fibrillation investigators. J Am Coll Cardiol 2000;35:183–7. https:// doi.org/10.1016/S0735-1097(99)00489-1 285. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008;29:915–22. https://doi.org/10.1093/eurheartj/ehn101 286. Ruff CT. AZALEA-TIMI 71 Steering Committee. Abelacimab, a novel factor XI/XIa inhibitor, vs rivaroxaban in patients with atrial fibrillation: primary results of the AZALEA-TIMI 71 randomized trial. Circulation 2024;148:e282–317. https://doi.org/ 10.1161/CIR.0000000000001200 287. Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, et al. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dosefinding phase 2 study. Lancet 2022;399:1383–90. https://doi.org/10.1016/S0140- 6736(22)00456-1 288. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a systematic review. Br J Clin Pharmacol 2021;87:352–74. https://doi.org/10.1111/bcp. 14404 289. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095–106. https://doi.org/10.1001/archinte.165.10.1095 290. Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics 2022;14:1120. https://doi.org/10.3390/pharmaceutics14061120 291. Mar PL, Gopinathannair R, Gengler BE, Chung MK, Perez A, Dukes J, et al. Drug interactions affecting oral anticoagulant use. Circ Arrhythm Electrophysiol 2022;15:e007956. https://doi.org/10.1161/CIRCEP.121.007956 292. Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patientlevel network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022;145:242–55. https://doi.org/10.1161/ CIRCULATIONAHA.121.056355 293. Kotecha D, Pollack CV, Jr, De Caterina R, Renda G, Kirchhof P. Direct oral anticoagulants halve thromboembolic events after cardioversion of AF compared with warfarin. J Am Coll Cardiol 2018;72:1984–6. https://doi.org/10.1016/j.jacc.2018.07.083 294. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 2022;387:978–88. https://doi.org/10.1056/NEJMoa2209051 295. Halperin JL, Hart RG, Kronmal RA, McBride R. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994;343:687–91. https://doi.org/10.1016/S0140-6736(94)91577-6 296. Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW, et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505–11. https://doi.org/10.1056/ NEJM199011293232201 297. Gulløv AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: second Copenhagen atrial fibrillation, aspirin, and anticoagulation study. Arch Intern Med 1998;158:1513–21. https://doi. org/10.1001/archinte.158.14.1513 298. Blackshear JL, Halperin JL, Hart RG, Laupacis A. Adjusted-dose warfarin versus lowintensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348: 633–8. https://doi.org/10.1016/S0140-6736(96)03487-3 299. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use–learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. J Thromb Thrombolysis 2014;38:150–9. https://doi.org/10.1007/s11239-013-1048-z 300. Själander S, Sjögren V, Renlund H, Norrving B, Själander A. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Thromb Res 2018;167:113–8. https://doi.org/10.1016/j.thromres.2018.05.022 301. van Miert JHA, Kooistra HAM, Veeger N, Westerterp A, Piersma-Wichers M, Meijer K. Choosing between continuing vitamin K antagonists (VKA) or switching to a direct oral anticoagulant in currently well-controlled patients on VKA for atrial fibrillation: a randomised controlled trial (GAInN). Br J Haematol 2019;186:e21–3. https://doi.org/ 10.1111/bjh.15856 302. Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P, Sairat P, Lip GYH. Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with non-valvular atrial fibrillation: a report from the nationwide COOL-AF registry. J Clin Med 2020;9:1698. https://doi.org/10.3390/jcm9061698 303. Szummer K, Gasparini A, Eliasson S, Ärnlöv J, Qureshi AR, Bárány P, et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. J Am Heart Assoc 2017;6:e004925. https://doi. org/10.1161/JAHA.116.004925 304. Cardoso R, Ternes CMP, Justino GB, Fernandes A, Rocha AV, Knijnik L, et al. Non-vitamin K antagonists versus warfarin in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis. Am J Med 2022;135:228–- 234.e1. https://doi.org/10.1016/j.amjmed.2021.08.026 305. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84–91. https://doi. org/10.1161/CIRCOUTCOMES.108.796185 306. Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS One 2017;12:e0188482. https://doi.org/10.1371/journal.pone.0188482 307. Macaluso GP, Pagani FD, Slaughter MS, Milano CA, Feller ED, Tatooles AJ, et al. Time in therapeutic range significantly impacts survival and adverse events in destination therapy patients. ASAIO J 2022;68:14–20. https://doi.org/10.1097/MAT.0000000000001572 308. Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379:322–34. https://doi.org/10.1016/S0140-6736(11)61294-4 309. Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation 2024;149:279–89. https://doi.org/10.1161/ CIRCULATIONAHA.123.066485 310. Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017;69:2779–90. https://doi.org/10.1016/j.jacc.2017.03.600 311. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol 2016;68:2597–604. https://doi.org/10.1016/j. jacc.2016.09.966 312. Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, et al. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:673–81. https://doi.org/10.1001/jamacardio. 2016.1829 313. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists. Thromb Haemost 2016;116:754–63. https://doi.org/10.1160/TH16-03-0203 314. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: global registry on long-term antithrombotic treatment in patients with atrial fibrillation (GLORIA-AF) registry. Am Heart J 2018;198:55–63. https://doi.org/10. 1016/j.ahj.2017.08.018 315. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al. XANTUS: a realworld, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145–53. https://doi.org/10.1093/ eurheartj/ehv466 316. Martinez CAA, Lanas F, Radaideh G, Kharabsheh SM, Lambelet M, Viaud MAL, et al. XANTUS-EL: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. Egypt Heart J 2018;70:307–13. https://doi.org/10. 1016/j.ehj.2018.09.002 317. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost 2017;117:1072–82. https://doi.org/10.1160/TH17-01-0068 318. Lee SR, Choi EK, Han KD, Jung JH, Oh S, Lip GYH. Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety. J Am Coll Cardiol 2018;72:838–53. https:// doi.org/10.1016/j.jacc.2018.05.066 319. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35:3346–55. https://doi.org/10.1093/eurheartj/ehu367 320. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388: 1995–2003. https://doi.org/10.1016/S0140-6736(16)31474-X ESC Guidelines 3391 Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026